Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid or Parathyroid Surgery

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05851560
Collaborator
(none)
45
1
3
7
6.4

Study Details

Study Description

Brief Summary

Despite use of meticulous surgical techniques and regardless of surgical access via conventional open or endoscopy, postoperative adhesions develop in the vast majority of patients undergoing neck surgery. Such adhesions represent not only adhesion reformation at sites of adhesiolysis, but also de novo adhesion formation at sites of surgical procedures. Improved understanding of the pathophysiology of adhesion development and distinguishing variations in the molecular biologic mechanisms represent future opportunities to improve the reduction of postoperative adhesions.

After surgical tissue injury, there were local release of histamine, cytokines, and growth factors that lead to adhesion development. Other than survival or safety issues, cosmetics concerns and quality of life are the motifs after thyroid surgeries currently. Pos-thyroidectomy adhesions include various symptoms such as neck discomfort, neck tightness, skin adhesion to the trachea, skin scarring from adhesive reaction, and vocal cord palsy or impairment of laryngeal vertical movement. Relief of the adhesion through wound massage or anti-adhesion agents could reduce neck discomfort and voice changes.Although oxidized regenerated cellulose (ORC) and hyaluronic acid (HA) appeared to be safe and effective to decrease the incidence of adhesions, to improve adhesion-related neck discomfort, and to prevent skin adhesion to the trachea after neck surgery. The application of antiadhesive barriers after neck surgery is safe but the effect is still uncertain. Thus, we aim to confirm the antiadhesive effect of multiple antiadhesive barriers in thyroid/parathyroid surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: Oxidized regenerated cellulose(ORC)
  • Drug: Hyaluronic acid(HA)
Phase 1

Detailed Description

The postsurgical adhesions remain a significant cause of morbidity for a large number of patients in thyroid and parathyroid surgeries, despite use of meticulous surgical techniques and regardless of surgical access via conventional open or endoscopy. Such adhesions represent not only adhesion reformation at sites of adhesiolysis, but also de novo adhesion formation at sites of surgical procedures. A number of products, in the form of film or fluid, are used to prevent postoperative adhesion formation. These products normally serve as barriers to separate the contact of the damaged tissue surfaces in many animal models and some clinical practices. However, there are few evidences for surgeons to use or no use, or choose the suitable products in their clinical practice in neck surgeries. Improved understanding of the pathophysiology of adhesion development and distinguishing variations in the molecular biologic mechanisms represent future opportunities to improve the reduction of postoperative adhesions.

After surgical tissue injury, there were local release of histamine, cytokines, and growth factors that lead to adhesion development . Local tissue inflammation processes initiate capillary leakage of serosanguineous fluid including clotting factors, and recruitment of macrophages and other cells, including fibroblasts. Cutting, fulguration, ligation of the macrovasculature and microvasculature leads to a state of tissue hypoxemia. Along with the accumulation of metabolic byproducts such as lactic acid, the lowering the pH of the injured tissue, and the conversion from aerobic to anaerobic metabolism within the injured tissues. Tissue hypoxia also results in creation of oxidative stress, with production of oxygen and nitrogen free radicals, which can result in DNA mutations, alterations of mitochondrial DNA, and generation of oxidized proteins.

Subsequently induce lipid peroxidation and protein nitration. The known factors involved in the inflammatory-like response that lead to adhesion development, are type 1 collagen, transforming growth factor b1 (TGF-b1), tumor necrosis factor a (TNF-a), interleukin 6 (IL-6), and vascular endothelial growth factor (VEGF). Of note, the scavenging of free radicals such as superoxide by superoxide dismutase can prevent the development of the adhesion phenotype . Other processes affected include plasminogen activator activity (PAA) (a function of tissue plasminogen activator and its inhibitor, plasminogen activator inhibitor-1), metalloproteinase activity, and extracellular matrix deposition (such as collagen 1, collagen 3, and fibronectin). There is also initiation of processes leading to angiogenesis, which can lead to new vessel formation that could resupply oxygen to these tissues as well as remove metabolic byproducts.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid or Parathyroid Surgery
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

control group that does not use antiadhesive material

Experimental: Oxidized regenerated cellulose(ORC) Group

The group that uses Oxidized regenerated cellulose(ORC) as antiadhesive material during thyroid surgery.

Drug: Oxidized regenerated cellulose(ORC)
Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
Other Names:
  • Anti-Adhesion Agent
  • Experimental: Hyaluronic acid(HA) Group

    The group that uses Hyaluronic acid(HA) as antiadhesive material during thyroid surgery.

    Drug: Hyaluronic acid(HA)
    Hyaluronic acid(HA)
    Other Names:
  • Anti-Adhesion Agent
  • Outcome Measures

    Primary Outcome Measures

    1. Chinese version of Dysphagia Handicap Index(DHI) [pre-operation]

      Evaluate the swallowing difficulty

    2. Chinese version of Dysphagia Handicap Index(DHI) [post-operation(week 2)]

      Evaluate the swallowing difficulty

    3. Chinese version of Dysphagia Handicap Index(DHI) [post-operation( month1)]

      Evaluate the swallowing difficulty

    4. Chinese version of Dysphagia Handicap Index(DHI) [post-operation(month 6)]

      Evaluate the swallowing difficulty

    5. Chinese version of Dysphagia Handicap Index(DHI) [post-operation( month12)]

      Evaluate the swallowing difficulty

    Secondary Outcome Measures

    1. Adhesion severity [post-operation(week 2)]

      Evaluate the adhesion severity by using questionnaires

    2. Adhesion severity [post-operation(month1)]

      Evaluate the adhesion severity by using questionnaires

    3. Adhesion severity [post-operation(month 6)]

      Evaluate the adhesion severity by using questionnaires

    4. Adhesion severity [post-operation(month12)]

      Evaluate the adhesion severity by using questionnaires

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age more than 20 years of age.

    • Patients diagnosed with benign goiter or thyroid cancer that will undergo open thyroidectomy (either unilateral or bilateral total thyroidectomy with or without central lymph node dissection).

    • Naïve patients to thyroid surgery.

    • Subjects are willing to comply with all aspects of the study and have signed informed consent form.

    Exclusion Criteria:
    • Pregnant or lactating female patients.

    • Presence of severe and uncontrolled illness such as stroke, hypertension, diabetes, chronic renal failure, coagulopathy.

    • Concurrent diseases/conditions which will be unable to evaluate the outcomes.

    • Patients with previous neck radiotherapy within 1 year.

    • Patients receiving any adhesion prevention adjuvant.

    • Previous history of Keloid or hypertrophic scar.

    • Participate are hypersensitive to anti-adhesion agents.

    • Participate in another clinical trial within 1 month.

    • Participate have drug or alcohol abuse.

    • Patients' presence of surgical site infection or uncontrolled bleeding.

    • Anticoagulant used within a week from surger

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Taiwan University Hospital Taipei Taiwan 100229

    Sponsors and Collaborators

    • National Taiwan University Hospital

    Investigators

    • Study Chair: Ming Hsun Wu, MD,PhD

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    National Taiwan University Hospital
    ClinicalTrials.gov Identifier:
    NCT05851560
    Other Study ID Numbers:
    • 202111057DINB
    First Posted:
    May 9, 2023
    Last Update Posted:
    May 9, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 9, 2023